Possibia

6283966

Last Update Posted: 2025-04-24

Recruiting

All Genders

accepted

40 Years-80 Years

5000 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.

Eligibility

Relevant conditions:

COPD (Chronic Obstructive Pulmonary Disease)

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com

1-877-240-9479

Data sourced from ClinicalTrials.gov